Other

Mayo Foundation for Medical Education and Research

Tillotts Pharma Ag

J. B. Tillott Limited

John Rhodes

Brian K Evans

William J Sandborn

Peter Rhodes

Brian Kenneth Evans

William E Douglas

Constipation and Irritable Bowel Syndrome are treated by a delayed and sustained release composition of an opioid antagonist which commences release of the opioid antagonist in the mid to distal small intestine or ascending colon and provides sustained release along any remaining part of the small intestine and along the colon. Preferred opioid antagonists are naloxone and naltrexone.

Composition for treatment of constipation and irritable bowel syndrome

A delayed and sustained release composition of an additive and/or toxic agent such as nicotine is delivered systemically in therapeutic amounts while avoiding the peak plasma levels which gives rise to addiction and/or toxic side effects. The composition is delivered for absorption predominantly from the colon.

Intestinal absorption of nicotine to treat nicotine responsive conditions

A method is provided to treat inflammatory bowel disease by locally administering to the colon an effective amount of nicotine or a pharmaceutically acceptable salt thereof, preferably via formulations adapted for delayed oral release or rectal administration. Further provided is a novel formulation for the oral administration of nicotine comprising a polyacrylic polymer complexed with nicotine.

Colonic delivery of nicotine to treat inflammatory bowel disease

Pharmaceutical products containing a complex of an amide-type local

Products and processes for the treatment of the alimentary canal

A solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent is coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH7 but soluble in colonic intestinal juice, in a sufficient amount that the oral dosage form remains intact until it reaches the colon. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. The invention has particular application to dosage forms of prednisolone and salts thereof, indomethacin, ibuprofen, and, especially, 5-amino-salicylic acid.

Orally administrable pharmaceutical composition

Orally administrable pharmaceutical compositions

Delayed release oral dosage forms for treatment of intestinal disorders

Essential Oils (including Arematic Carminatives) and their active components are selectively administered to the intestine to treat irritable colon syndron and other intestinal disorders responsive to treatment with a carminative. The oils are presented in a rectal or, preferably, enteric preparation, especially an enterically coated hard gelatine capsule. Peppermint oil is presently preferred.

Method of treating functional bowel disorders by the administration of

An adhesive composition consisting essentially of a poly (lower alkyl) methacrylate, a liquid plasticizer, an inert particulate filler, and a chlorinated rubber; and a method of using the same to secure the pouch of an ileostomy, ureterostomy, colostomy or the like appliance to the skin.

Growing community of inventors

Cardiff, United Kingdom

John Rhodes